HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

David A Braun¹, Marcus S Noel², Ryan H Moy³, Kurt Demel⁴, Martin Gutierrez⁵, Sunil Sharma⁶, Arif Hussain⁷, Shirish Gadgeel⁸, Julio Peguero⁹, Toni K Choueiri¹⁰, Hamid Emamekhoo¹¹, Brian Van Tine¹², Rama Balaraman¹³, GiNell Elliott¹⁴, Sritama Nath¹⁴, Scott R Daigle¹⁴, Pavan Kumar¹⁴, Anita Scheuber¹⁵, David Sommerhalder¹⁶

¹Yale School of Medicine, New Haven, CT, USA. Electronic address: david.braun@yale.edu.

²Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington, DC, USA.

³Columbia University Irving Medical Center, New York, NY, USA.

⁴HealthPartners, St. Louis Park, MN, USA.

⁵Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, NJ, USA.

⁶Honor Health Research Institute, Scottsdale, AZ, USA.

⁷University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

⁸Henry Ford Cancer Institute, Henry Ford Health Center, Detroit, MI, USA.

⁹Oncology Consultants, Houston, TX, USA.

¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

¹¹University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

¹²Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.

¹³Florida Cancer Affiliates-US Oncology, Ocala, FL, USA.

¹⁴Nimbus Therapeutics, Boston, MA, USA.

¹⁵Nimbus Therapeutics, Boston, MA, USA. Electronic address: anita.scheuber@nimbustx.com.

¹⁶NEXT Oncology, San Antonio, TX, USA.

PubMed PMC DOI PDF

Abstract

Hematopoietic progenitor kinase 1 (HPK1) induces potent anti-tumor immunity in preclinical models by activating and recruiting T cells, B cells, and dendritic cells into the tumor microenvironment (TME). Here, we evaluate NDI-101150, a potent, selective HPK1 inhibitor, in a phase 1/2 trial as a monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The monotherapy…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.